Invasive fungal infections are a common problem in liver transplant recipients. Winston et al. performed a randomized, double-blind trial of anidulafungin versus fluconazole in 200 high-risk liver transplant recipients. Both drugs were well tolerated, and graft rejection, fungal-free survival and mortality were similar in both groups. However, anidulafungin was associated with less Aspergillus colonization, and with fewer breakthrough invasive fungal infections in patients who had received pretransplant fluconazole.